摘要:
The invention relates to novel thiazolidine-4(S)-carboxylic acid derivatives of the general formula (I) ##STR1## wherein R.sup.1 stands for an optionally substituted furyl, pyrrolyl, thienyl, benzofuryl, benzopyrrolyl, benzothienyl, phenyl, pyridyl, quinolinyl, isoquinolinyl or indanyl group or a C.sub.1-4 alkyl or C.sub.2-4 alkenyl group optionally substituted by a hydroxyl, carboxyl or halogen fenoxy group,stands for hydrogen, an alkaline metal or an alkaline earth metal atom or an optionally substituted C.sub.1-4 alkyl group or aryl group;R.sup.3 represents hydrogen or an optionally substituted C.sub.1-4 alkyl or acyl group or aryl groupas well as their salts.Further on, the invention relates to pharmaceutical preparations containing these compounds and to a process for preparing these compounds and preparations.The compounds of the invention are useful for treating or preventing liver damages of either natural or experimental origin.
摘要:
There are disclosed pharmaceutical compositions comprising at least one cytostatic agent and N.sup..epsilon. -trimethylthyllysin or a pharmaceutically acceptable salt thereof, optionally in association with conventional pharmaceutical carriers and other additives.The new compositions possess a reduced toxicity compared with the cytostatic agents administered alone.
摘要:
The invention relates to new peptide derivatives of the general Formula I ##STR1## wherein R is a group derived from any oligopeptide by removing a terminal amino group, or--if the oligopeptide comprises a diamino carboxylic acid--the amino group in the .omega.-position, or the terminal and .omega.-amino groups; andstands for the integral number 1 or 2and acid addition slats thereof and a process for the preparation thereof.The new compounds of the general Formula I exhibit antitumor activity.
摘要:
The present invention relates to synergistic pharmaceutical compositions for the treatment of liver disorders comprising 5-aminoimidazole-4-carboxamide orthophosphate (AICA-phosphate) as active ingredient in association with vitamins, preferably with vitamin B and/or E and optionally with other pharmaceutical excipients.